Celltrion Inc sales and marketing update

Celltrion launched Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) in 12 European countries. Remsima is available in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the U.K.

The chimeric mAb against tumor necrosis factor (TNF) alpha is indicated to treat Crohn’s disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), ankylosing spondylitis, psoriasis and psoriatic arthritis. Remsima is the first biosimilar mAb to be approved by the European Commission. An NDA for Remsima is under review in the U.S. ...